Shoichi Deguchi

ORCID: 0000-0003-2424-2314
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Glioma Diagnosis and Treatment
  • Brain Metastases and Treatment
  • Lung Cancer Research Studies
  • Meningioma and schwannoma management
  • Radiomics and Machine Learning in Medical Imaging
  • Hedgehog Signaling Pathway Studies
  • Epigenetics and DNA Methylation
  • Mathematical Biology Tumor Growth
  • Lung Cancer Treatments and Mutations
  • Cancer, Hypoxia, and Metabolism
  • Cancer Genomics and Diagnostics
  • Advanced Radiotherapy Techniques
  • Head and Neck Surgical Oncology
  • Pancreatic and Hepatic Oncology Research
  • MRI in cancer diagnosis
  • MicroRNA in disease regulation
  • Management of metastatic bone disease
  • Neurofibromatosis and Schwannoma Cases
  • Cancer Research and Treatments
  • Cancer-related molecular mechanisms research
  • Genetic and Kidney Cyst Diseases
  • Lanthanide and Transition Metal Complexes
  • Sarcoma Diagnosis and Treatment
  • Cardiac tumors and thrombi
  • Protein Degradation and Inhibitors

Nagoya University
2017-2025

Shizuoka Cancer Center
2017-2024

Nagoya University Hospital
2024

Shizuoka Medical Center
2019-2023

Nagoya City University
2017

JEOL (Japan)
2006

Abstract T2-FLAIR mismatch sign is known as a highly specific imaging marker of IDH-mutant astrocytomas. This study was intended to clarify what the represents by pathological analysis lower-grade gliomas rediagnosed in accordance with WHO 2016 classification. We retrospectively analyzed records 64 patients diagnosed grade II and III diffuse between June 2009 November 2018. found 10 (45%) out 22 astrocytoma, 1 (5%) 20 oligodendroglioma, IDH-wild-type astrocytoma. astrocytomas showed positive...

10.1038/s41598-020-67244-7 article EN cc-by Scientific Reports 2020-06-22

Glioblastoma (GB) is the most common and aggressive primary malignant brain tumor in adults. To date, no effective treatment has been reported for recurrent GB (rGB). Long noncoding RNA taurine upregulated gene 1 (TUG1), which highly expressed GB, resolves formation of R-loops, thereby maintaining growth. TUG1-targeting antisense oligonucleotide (ASO) (TUG1ASO) a nucleotide therapeutic with drug delivery system that targets TUG1, demonstrating efficacy against mouse models. This multicenter,...

10.1186/s12885-025-13623-0 article EN cc-by-nc-nd BMC Cancer 2025-02-13

Diffuse hemispheric glioma H3 G34-mutant (DHG) has been identified as a distinct pediatric-type high-grade glioma, according to the World Health Organization (WHO) classification of central nervous system tumors. Widely accepted treatment options include surgery, radiation, and conventional chemotherapy. However, efficacy surgical resection remains unclear. Although there are some reports, comprehensive understanding clinical characteristics, pathogenesis, outcomes DHG is insufficient...

10.1186/s40478-025-01945-w article EN cc-by-nc-nd Acta Neuropathologica Communications 2025-02-27

Background/Aim: Glioblastoma multiforme (GBM) is an intractable tumor that has a very poor prognosis despite intensive treatment with temozolomide plus radiotherapy. Patients and Methods: Sixteen newly diagnosed patients high-grade gliomas were enrolled in phase II study of the α-type-1 DC vaccine. Briefly, DCs obtained from culture enriched monocytes presence cytokine cocktail, pulsed cocktail 5 synthetic peptides cryopreserved until injection into patients. Results: The amount IL-12...

10.21873/anticanres.14669 article EN Anticancer Research 2020-10-27

Purpose Management of leptomeningeal metastasis-related hydrocephalus (LM-H) is particularly challenging regarding the control severe headache, nausea, and vomiting due to intracranial hypertension. To investigate improvements performance status outcome with cerebrospinal fluid (CSF) shunt surgery for LM-H in patients lung adenocarcinoma. Methods Data on from adenocarcinoma diagnosed by MR imaging and/or cytological examination were retrospectively analyzed. Between August 2008 July 2017,...

10.1371/journal.pone.0210074 article EN cc-by PLoS ONE 2019-01-10

Recently, clinical studies using anti-immune checkpoint molecule antibodies have been successful in solid tumors, such as melanoma and non-small cell lung cancers. However, pancreatic cancers are still intractable difficult to treat once recurrence or metastasis occurs; thus, novel combined use of immune blockade (ICB) with molecular targeted drugs is considered a therapeutic option. Previously, we developed humanized MHC-double knockout (dKO) NOG mouse model demonstrated that an anti-PD-1...

10.1016/j.imlet.2019.10.003 article EN cc-by-nc-nd Immunology Letters 2019-10-03

Background/Aim: Brain metastasis, a leading cause of cancer death, is clinical challenge. Recently, genetic characterization brain metastatic lesions based on next generation sequencing-based advanced technologies, such as single-cell RNA sequencing, has been performed to develop novel efficient therapies. The present study aimed investigate brain-metastasis-specific biomarkers well relevant prognostic factors. Patients and Methods: profiles expression levels immune response-associated genes...

10.21873/anticanres.17001 article EN cc-by-nc-nd Anticancer Research 2024-04-27

Abstract Background This study aimed to investigate what treatment are selected for malignant brain tumors, particularly glioblastoma (GBM) and primary central nervous system lymphoma (PCNSL), in real-world Japan the costs involved. Methods We conducted a questionnaire survey regarding selections newly diagnosed GBM PCNSL treated between July 2021 June 2022 among 47 institutions Clinical Oncology Group-Brain Tumor Study Group. calculated total cost per month of initial therapy or PCNSL....

10.1093/jjco/hyae116 article EN cc-by-nc Japanese Journal of Clinical Oncology 2024-09-02

This study demonstrates a transmission electron microscopy based system that enables simultaneous measurements of conductivity and magnetism in nanoscale area. A double-probe piezodriving holder is developed order to determine the any part thin-foil specimen. The measurement can be combined with holography, which used obtain magnetic flux map same applied extensively for research development electronic and/or materials.

10.1063/1.2208384 article EN Applied Physics Letters 2006-05-29

Abstract Isocitrate dehydrogenase-mutant low-grade gliomas (IDHmut-LGG) grow slowly but frequently undergo malignant transformation, which eventually leads to premature death. Chemotherapy and radiotherapy treatments prolong survival, can also induce genetic (or epigenetic) alterations involved in transformation. Here, we developed a mathematical model of tumor progression based on serial volume data treatment history 276 IDHmut-LGGs classified by chromosome 1p/19q codeletion...

10.1158/0008-5472.can-21-0985 article EN cc-by-nc-nd Cancer Research 2021-07-31

Abstract Background Stereotactic irradiation (STI) is a primary treatment for patients with newly diagnosed brain metastases. Some of these experience local progression, which difficult to differentiate from radiation necrosis, and treat. So far, just few studies have clarified the prognosis effectiveness salvage surgery after STI. We evaluated diagnostic value improvement functional outcomes surgery. Based on results, we reconsidered surgical indication progression Methods metastases...

10.1186/s12885-020-06800-w article EN cc-by BMC Cancer 2020-04-17

The safety and effectiveness of neoadjuvant fractionated stereotactic radiotherapy (FSRT) before piecemeal resection brain metastasis (BM) remains unknown.

10.1007/s10147-021-02083-8 article EN cc-by International Journal of Clinical Oncology 2021-11-18

Abstract Gliomas are classified by combining histopathologic and molecular features, including isocitrate dehydrogenase (IDH) status. Although IDH-wild-type diffuse astrocytic glioma (DAG) shows a more aggressive phenotype than IDH-mutant type, lack of knowledge regarding relevant drivers for this type tumor has hindered the development therapeutic agents. Here, we examined human DAGs mouse model with mosaic analysis double markers (MADM) system, which concurrently lacks p53 NF1...

10.1158/0008-5472.can-19-1272 article EN Cancer Research 2019-08-20
Coming Soon ...